| [1] |
Cabrera-Fuentes H, Aragones J, Bernhagen J, et al. From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on "New frontiers in cardiovascular research"[J]. Basic Res Cardiol, 2016, 111(6): 69-75. doi: 10.1007/s00395-016-0586-x
|
| [2] |
Xia Z, Li H, Irwin MG. Myocardial ischaemia reperfusion injury:the challenge of translating ischaemic and anaesthetic protection from animal models to humans[J]. Br J Anaesth, 2016,11(7): 44-62. https://academic.oup.com/bja/article/117/suppl_2/ii44/2237262
|
| [3] |
Marber MS, Latchman DS, Walker JM, et al. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction[J]. Circulation, 1993, 88(3): 1264-72. doi: 10.1161/01.CIR.88.3.1264
|
| [4] |
Hausenloy DJ, Yellon DM. The second window of preconditioning(SWOP)where are we now[J]. Cardiovasc Drugs Ther, 2010, 24(3): 235-54. doi: 10.1007/s10557-010-6237-9
|
| [5] |
Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection[J]. Heart Fail Rev, 2007, 12(3/4): 217-34. doi: 10.1007/s10741-007-9026-1
|
| [6] |
Hausenloy DJ, Lecour S, Yellon DM. Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin[J]. Antioxid Redox Signal, 2011, 14(5): 893-907. doi: 10.1089/ars.2010.3360
|
| [7] |
Hausenloy DJ, Barrabes JA, Botker HE, et al. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery[J]. Basic Res Cardiol, 2016, 111(6): 70-8. doi: 10.1007/s00395-016-0588-8
|
| [8] |
Varga ZV, Giricz Z, Bencsik P, et al. Functional genomics of cardioprotection by ischemic conditioning and the influence of comorbid conditions: implications in target identification[J]. Curr Drug Targets, 2015, 16(8): 904-11. doi: 10.2174/1389450116666150427154203
|
| [9] |
Williams RP, Manou-Stathopoulou V, Redwood SR, et al. 'Warm-up Angina': harnessing the benefits of exercise and myocardial ischaemia[J]. Heart, 2014, 100(2): 106-14. doi: 10.1136/heartjnl-2013-304187
|
| [10] |
Di LF, Bernardi P. Mitochondria and ischemia-reperfusion injury of the heart: fixing a hole[J]. Cardiovasc Res, 2006, 70(2): 191-9. doi: 10.1016/j.cardiores.2006.01.016
|
| [11] |
Walsh SR, Tang TY, Kullar P, et al. Ischaemic preconditioning during cardiac surgery:systematic review and meta-analysis of perioperative outcomes in randomised clinical trials[J]. Eur J Cardiothorac Surg, 2008, 34(5): 985-94. doi: 10.1016/j.ejcts.2008.07.062
|
| [12] |
Zhao ZQ. Postconditioning in reperfusion injury: a status report[J]. Cardiovasc Drugs Ther, 2010, 24(3): 265-79. doi: 10.1007/s10557-010-6240-1
|
| [13] |
Hausenloy DJ. Cardioprotection techniques: preconditioning,postconditioning and remote conditioning(basic science) [J].Curr Pharm Des, 2013, 19(25): 4544-63. doi: 10.2174/1381612811319250004
|
| [14] |
Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart[J]. Circulation, 2005, 112(14): 2143-8. doi: 10.1161/CIRCULATIONAHA.105.558122
|
| [15] |
Halestrap AP, Richardson AP. The mitochondrial permeability transition: A current perspective on its identity and role in ischaemia/reperfusion injury[J]. J Mol Cell Cardiol, 2015, 78(12): 129-41. https://www.sciencedirect.com/science/article/pii/S002228281400265X
|
| [16] |
Araszkiewicz A, Grygier M, Pyda MA, et al. Postconditioning reduces enzymatic infarct size and improves microvascular reperfusion in patients with ST-Segment elevation myocardial infarction[J]. Cardiology, 2014, 129(4): 250-7. doi: 10.1159/000367965
|
| [17] |
Liu BS, Xu F, Wang JL, et al. The cardioprotection of ischemic postconditioning in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Int J Cardiol, 2015, 178(6): 181-3.
|
| [18] |
Luo WJ, Li B, Lin GQ, et al. Postconditioning in cardiac surgery for tetralogy of Fallot[J]. J Thorac Cardiovasc Surg, 2007, 133(5): 1373-4. doi: 10.1016/j.jtcvs.2007.01.028
|
| [19] |
Sivaraman V, Mudalagiri NR, Di Salvo CA, et al. Postconditioning protects human atrial muscle through the activation of the RISK pathway[J]. Basic Res Cardiol, 2007, 102(5): 453-9. doi: 10.1007/s00395-007-0664-1
|
| [20] |
Eitel I, Stiermaier T, Rommel KP, et al. Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized Lipsia Conditioning trial[J]. Eur Heart J, 2015, 36(44, SI): 3049-55. doi: 10.1093/eurheartj/ehv463
|
| [21] |
Roolvink V, Ottervanger JP, Ibáñez B, et al. One year clinical outcome of early administration of intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary reperfusion[J]. EuroIntervention, 2017,72(4):125-34.
|
| [22] |
Cung TT, Morel O, Cayla G, et al. Cyclosporine before PCI in Patients with Acute Myocardial Infarction[J]. N Engl J Med, 2015, 373(11): 1021-31. doi: 10.1056/NEJMoa1505489
|
| [23] |
Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction(J-WIND):two randomised trials[J]. Lancet, 2007, 370(9597): 1483-93. doi: 10.1016/S0140-6736(07)61634-1
|
| [24] |
Woo JS, Kim W, Ha SJ, et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study[J]. Arterioscler Thromb Vasc Biol, 2013, 33(9): 2252-60. doi: 10.1161/ATVBAHA.113.301586
|
| [25] |
Chang G, Liu J, Qin S, et al. Cardioprotection by exenatide:A novel mechanism via improving mitochondrial function involving the GLP-1 receptor/cAMP/PKA pathway[J]. Int J Mol Med, 2017,36(10):248-53. doi: 10.3892/ijmm.2017.3318
|
| [26] |
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015, 373(22): 2117-28. doi: 10.1056/NEJMoa1504720
|
| [27] |
Baartscheer A, Schumacher CA, Wust RC, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits[J]. Diabetologia, 2017, 60(3): 568-73. doi: 10.1007/s00125-016-4134-x
|
| [28] |
Kleinbongard P, Skyschally A, Heusch G. Cardioprotection by remote ischemic conditioning and its signal transduction[J]. Pflugers Arch, 2017, 469(2): 159-81. doi: 10.1007/s00424-016-1922-6
|
| [29] |
Hausenloy DJ, Yellon DM. Remote ischaemic preconditioning: underlying mechanisms and clinical application[J]. Cardiovasc Res, 2008, 79(3): 377-86. doi: 10.1093/cvr/cvn114
|
| [30] |
Rassaf T, Totzeck M, Hendgen-Cotta UB, et al. Circulating nitrite contributes to cardioprotection by remote ischemic preconditioning[J]. Circ Res, 2014, 114(10): 1601-10. doi: 10.1161/CIRCRESAHA.114.303822
|
| [31] |
Li J, Rohailla S, Gelber N, et al. MicroRNA-144 is a circulating effector of remote ischemic preconditioning[J]. Basic Res Cardiol, 2014, 109(5): 423-33. doi: 10.1007/s00395-014-0423-z
|
| [32] |
Davidson SM, Selvaraj P, He D, et al. Remote ischaemic preconditioning involves signalling through the SDF-1 alpha/CXCR4 signalling axis[J]. Basic Res Cardiol, 2013, 108(5): 377-82. doi: 10.1007/s00395-013-0377-6
|
| [33] |
Shimizu M, Tropak M, Diaz RJ, et al. Transient limb ischaemia remotely preconditions through a humoral mechanism acting directly on the myocardium: evidence suggesting cross-species protection[J]. Clin Sci (Lond), 2009, 117(5): 191-200. doi: 10.1042/CS20080523
|
| [34] |
Wang L, Oka N, Tropak M, et al. Remote ischemic preconditioning elaborates a transferable blood-borne effector that protects mitochondrial structure and function and preserves myocardial performance after neonatal cardioplegic arrest[J]. J Thorac Cardiovasc Surg, 2008, 136(2): 335-42. doi: 10.1016/j.jtcvs.2007.12.055
|
| [35] |
Steensrud T, Li J, Dai X, et al. Pretreatment with the nitric oxide donor SNAP or nerve transection blocks humoral preconditioning by remote limb ischemia or intra-arterial adenosine[J]. Am J Physiol Heart Circ Physiol, 2010, 299(5): H1598-603. doi: 10.1152/ajpheart.00396.2010
|
| [36] |
Redington KL, Disenhouse T, Strantzas SC, et al. Remote cardioprotection by direct peripheral nerve stimulation and topical capsaicin is mediated by circulating humoral factors[J]. Basic Res Cardiol, 2012, 107(2): 241-7. doi: 10.1007/s00395-011-0241-5
|
| [37] |
Redington KL, Disenhouse T, Li J, et al. Electroacupuncture reduces myocardial infarct size and improves post-ischemic recovery by invoking release of humoral, dialyzable, cardioprotective factors[J]. J Physiol Sci, 2013, 63(3): 219-23. doi: 10.1007/s12576-013-0259-6
|
| [38] |
Jensen RV, Støttrup NB, Kristiansen SB, et al. Release of a humoral circulating cardioprotective factor by remote ischemic preconditioning is dependent on preserved neural pathways in diabetic patients[J]. Basic Res Cardiol, 2012, 107(5): 285-9. doi: 10.1007/s00395-012-0285-1
|
| [39] |
Günaydin B, Cakici I, Soncul H, et al. Does remote organ ischaemia trigger cardiac preconditioning during coronary artery surgery[J]. Pharmacol Res, 2000, 41(4): 493-6. doi: 10.1006/phrs.1999.0611
|
| [40] |
Cheung MM, Kharbanda RK, Konstantinov IE, et al. Randomized controlled trial of the effects of remote ischemic preconditioning on children undergoing cardiac surgery: first clinical application in humans[J]. J Am Coll Cardiol, 2006, 47(11): 2277-82. doi: 10.1016/j.jacc.2006.01.066
|
| [41] |
Thielmann M, Kottenberg E, Kleinbongard P, et al. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial[J]. Lancet, 2013, 382(9892): 597-604. doi: 10.1016/S0140-6736(13)61450-6
|
| [42] |
Candilio L, Malik A, Ariti C, et al. Effect of remote ischaemic preconditioning on clinical outcomes in patients undergoing cardiac bypass surgery: a randomised controlled clinical trial[J]. Heart, 2015, 101(3): 185-92. doi: 10.1136/heartjnl-2014-306178
|
| [43] |
Hong DM, Lee EH, Kim HJ, et al. Does remote ischaemic preconditioning with postconditioning improve clinical outcomes of patients undergoing cardiac surgery? Remote Ischaemic Preconditioning with Postconditioning Outcome Trial[J]. Eur Heart J, 2014, 35(3): 176-84. doi: 10.1093/eurheartj/eht346
|
| [44] |
Meybohm P, Bein B, Brosteanu O, et al. A multicenter trial of remote ischemic preconditioning for heart surgery[J]. N Engl J Med, 2015, 373(15): 1397-407. doi: 10.1056/NEJMoa1413579
|
| [45] |
Hausenloy DJ, Candilio L, Evans R, et al. Remote ischemic preconditioning and outcomes of cardiac surgery[J]. N Engl J Med, 2015, 373(15): 1408-17. doi: 10.1056/NEJMoa1413534
|
| [46] |
Hoole SP, Heck PM, Sharples L, et al. Cardiac remote ischemic preconditioning in coronary stenting (CRISP stent) study: a prospective, randomized control trial[J]. Circulation, 2009, 119(6): 820-7. doi: 10.1161/CIRCULATIONAHA.108.809723
|
| [47] |
Liu Z, Wang YL, Xu D, et al. Late remote ischemic preconditioning provides benefit to patients undergoing elective percutaneous coronary intervention[J]. Cell Biochem Biophys, 2014, 70(1): 437-42. doi: 10.1007/s12013-014-9936-1
|
| [48] |
Bosnjak ZJ, Ge ZD. The application of remote ischemic conditioning in cardiac surgery[J]. F1000Res, 2017,23(6): 928-35. https://f1000researchdata.s3.amazonaws.com/manuscripts/11880/1bcb2540-a992-4fd7-8b67-81f33079ff57_11018_-_zeljko_bosnjak.pdf?doi=10.12688/f1000research.11018.1
|
| [49] |
Kanazawa H, Tseliou E, Malliaras KA, et al. Cellular postconditioning allogeneic Cardiosphere-Derived cells reduce infarct size and attenuate microvascular obstruction when administered after reperfusion in Pigs with acute myocardial infarction[J]. Circ Heart Fail, 2015, 8(2): 322-32. doi: 10.1161/CIRCHEARTFAILURE.114.001484
|
| [50] |
de Couto G, Liu WX, Tseliou E, et al. Macrophages mediate cardioprotective cellular postconditioning in acute myocardial infarction[J]. J Clin Invest, 2015, 125(8): 3147-62. doi: 10.1172/JCI81321
|
| [51] |
Kloner RA. Current state of clinical translation of cardioprotective agents for acute myocardial infarction[J]. Circ Res, 2013, 113(4): 451-63. doi: 10.1161/CIRCRESAHA.112.300627
|
点击查看大图
下载:
